Anixa Biosciences, Inc. (ANIX)

Market Cap	97.24M
Revenue (ttm)	n/a
Net Income (ttm)	-12.55M
Shares Out	32.19M
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	206,328
Open	3.110
Previous Close	2.810
Day's Range	3.000 - 3.155
52-Week Range	2.070 - 4.940
Beta	0.91
Analysts	Strong Buy
Price Target	8.50 (+181.42%)
Earnings Date	Jan 10, 2025

About ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company’s vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the develo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 1, 1987
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: ANIX
• Website: https://www.anixa.com

Analyst Forecast

According to 2 analysts, the average rating for ANIX stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 181.42% from the latest price.

Price Target

$8.5

(181.42% upside)

Analyst Consensus: Strong Buy